See more : G.M. Breweries Limited (GMBREW.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Quest PharmaTech Inc. (QPTFF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Quest PharmaTech Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- China Boton Group Company Limited (3318.HK) Income Statement Analysis – Financial Results
- Cornerstone FS plc (CSFS.L) Income Statement Analysis – Financial Results
- Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (T14.SI) Income Statement Analysis – Financial Results
- Tarini International Limited (TARINI.BO) Income Statement Analysis – Financial Results
- Tai Industries Limited (TAIIND.BO) Income Statement Analysis – Financial Results
Quest PharmaTech Inc. (QPTFF)
About Quest PharmaTech Inc.
Quest PharmaTech Inc., a pharmaceutical company, develops antibody based immunotherapeutic products for cancer. Its lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16, for targeted cancer therapy applications. The company also offers Oregovomab, an anti-CA-125 antibody, which has completed Phase II clinical trial for the treatment of ovarian cancer. In addition, it develops, manufactures, and commercializes immunotherapy products for pancreatic cancer. Further, the company develops products by using proprietary transdermal delivery technologies for dermatology and wound healing applications; skin penetrating active molecules for cosmetic and pharmaceutical use; and combinatorial immunotherapeutic products for the treatment cancer by using monoclonal antibodies of the immunoglobulin of G and E class. Quest PharmaTech Inc. is headquartered in Edmonton, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 542.86K | 336.23K | 170.24K | 212.51K | 11.26M |
| General & Administrative | 772.96K | 497.99K | 620.34K | 857.84K | 2.37M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 772.96K | 497.99K | 620.34K | 857.84K | 2.37M |
| Other Expenses | 0.00 | 450.00K | 241.26K | 213.82K | 0.00 |
| Operating Expenses | 1.32M | 834.22K | 790.57K | 1.07M | 13.29M |
| Cost & Expenses | 1.32M | 834.22K | 790.57K | 1.07M | 13.29M |
| Interest Income | 0.00 | 0.00 | 0.00 | 1.83K | 46.93K |
| Interest Expense | 20.68K | 21.00K | 13.06K | 7.77K | 0.00 |
| Depreciation & Amortization | 2.97K | 13.49K | 38.56K | 39.31K | 6.08K |
| EBITDA | -1.31M | -3.47M | -788.71K | -1.07M | -13.63M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -1.32M | -834.22K | -58.30M | 163.32M | -13.63M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -1.70M | -64.05M | -84.23M | 191.12M | 380.14K |
| Income Before Tax | -3.02M | -64.89M | -85.04M | 190.06M | -13.25M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -2.63M | -57.50M | 164.39M | -7.09M |
| Net Income | -3.02M | -64.89M | -85.04M | 190.06M | -6.16M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.02 | -0.39 | -0.51 | 1.13 | -0.04 |
| EPS Diluted | -0.02 | -0.39 | -0.51 | 1.11 | -0.04 |
| Weighted Avg Shares Out | 169.13M | 168.40M | 168.24M | 170.92M | 167.12M |
| Weighted Avg Shares Out (Dil) | 169.13M | 168.40M | 168.24M | 170.92M | 167.40M |
Source: https://incomestatements.info
Category: Stock Reports